SAR 440340

Drug Profile

SAR 440340

Alternative Names: REGN-3500; SAR440340

Latest Information Update: 31 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Regeneron Pharmaceuticals; Sanofi
  • Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Interleukin 1 receptor-like 1 protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic asthma
  • Phase I Inflammation

Most Recent Events

  • 12 Mar 2018 Phase-II clinical trials in Allergic asthma (Monotherapy) in USA (SC)
  • 13 Dec 2017 Regeneron plans a phase II proof-of-concept trial for Asthma in 2018 (NCT03387852)
  • 13 Dec 2017 Regeneron plans a phase II proof-of-concept trial for Chronic obstructive pulmonary disease in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top